– Collaboration expected to enable faster and deeper market penetration into growing global TTR amyloidosis market – The companies will jointly develop and commercialize eplontersen in the U.S., AstraZeneca has exclusive rights to commercialize in rest of the world – Bolsters Ionis’ commercial
Read more